RE:RE:RE:RE:RE:Any hope?Yes, the final proof will be in the clinic. Hopefully the Phase 1b data has low or no ARIA-E. That would be huge.
The hypothesis is already supported by the clinical data from competitors to date. PRX data should provide more support. PRX appears to be impacted by monomer competition and shows significant plaque binding. So I would expect less benefit from PRX and signficant ARIA-E.
I was a bit worried when the ACU193 Ph1 was showing ARIA-E, since Acumen had published an immunohistochemistry analysis that was pretty clean (they observed very minor plaque binding, and attributed it to an artifact). However, the poster presentation data from PMN shows a not-so-clean result for ACU193 with respect to plaque binding, which is consistent with the clinical trial result.